Why the study?
Does AAV-mediated delivery of a CaMKII peptide inhibitor suppress arrhythmias in preclinical models of CPVT?
Does AAV-mediated delivery of a CaMKII peptide inhibitor suppress arrhythmias in preclinical models of CPVT?
Gene therapy using AAV-mediated delivery of a CaMKII peptide inhibitor provides proof-of-concept for suppressing arrhythmias in CPVT.
Answers are grounded in this paper and cite their sources.
Supports preclinical AAV-CaMKII inhibition for CPVT; leaves open translation to human arrhythmia suppression.
This proof-of-concept study showed that AAV-mediated delivery of a CaMKII peptide inhibitor to the heart was effective in suppressing arrhythmias in a murine model of CPVT. CaMKII inhibition also reversed the arrhythmia phenotype in human CPVT induced pluripotent stem cell-derived cardiomyocyte models with different pathogenic mutations.
No takes yet. Share an insight, caveat, or question.
Bezzerides et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: